Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) exploit the concept of
synthetic lethality and offer great promise in the treatment of tumors with deficiencies in …

As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and
breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment …

Several poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved by FDA to
treat cancer with BRCA mutations. BRCA mutations are considered to fuel a PARPi killing …

Background and Objective: This review comprehensively explores the intricate landscape of
anaplastic lymphoma kinase (ALK), focusing specifically on its pivotal role in non-small cell …

Background Clear cell renal cell carcinoma (ccRCC) is a highly lethal malignancy with few
therapeutic options. Cyclin‑dependent kinase 9 (CDK9), a potential therapeutic target of …

Poly (adenosine 5′-diphosphate-ribose) polymerase inhibitors (PARPi) are increasingly
important in the treatment of ovarian cancer. However, more than 40% of BRCA1/2-deficient …

Abstract Background NOP2/Sun domain 2 (NSUN2) is one of the important RNA
methyltransferases catalyzing 5‐methylcytosine (m5C) formation and participates in many …

Abstract Cyclin-dependent kinase 9 (CDK9) inhibitors are a novel category of anticancer
treatment for cancers. However, their effects on hepatocellular carcinoma (HCC) are rarely …

The current review comprehensively explores the multifaceted landscape of anaplastic
lymphoma kinase (ALK) and its pivotal role, specifically within non-small cell lung cancer …

PARP inhibitors (PARPi) play an increasing role in the treatment of ovarian cancer (OC).
However, more than 40% BRCA1/2-deficient patients do not respond to PARPi, and wild …